
    
      Study Design:

      A total of 80 children with confirmed CPP were planned to be enrolled and randomized in a 1:1
      ratio to receive 2 injections of either leuprolide acetate 11.25 mg or 30 mg depot
      formulation, each injection administered 3 mo apart (6 mo of treatment):

      This study includes a 4-week Screening Period, two 3-mo treatment cycles, and a posttreatment
      follow-up period (12 weeks following the Mo 6 visit). Study visits will occur at Screening,
      Day 1, Week 2 (only for subjects participating in the pharmacokinetic subset), Mo 1, 2, 3, Mo
      6/Early Termination, and 12 weeks later, for the Posttreatment Follow-up Visit.

      This study was conducted at 18 sites in the United States and 4 sites in Puerto Rico.
    
  